ArticleEuropean journal of applied physiology2026
Cuminaldehyde alleviates rat diabetic tendinopathy and improves gait behavior via SOD restoration and AGER signaling axis inhibition.
Article in European journal of applied physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiabetic tendinopathy is an underrecognized complication of type 2 diabetes. Despite glycemic control with antidiabetic drugs, tendon structure and function often remain impaired. Plant-derived bioactive compounds offer dual benefits by lowering blood glucose while targeting tendon-specific pathology. This study evaluated the therapeutic potential and underlying mechanisms of cuminaldehyde (CA) on Achilles tendon properties in a type 2 diabetic rat model induced by a high-fat diet (HFD) combined with low-dose streptozotocin (STZ).
methodsA total of 24 male white Sprague-Dawley rats were randomly divided into four groups. Control (non-diabetic), diabetic (HFD + 35 mg/kg STZ), diabetic rats treated with low-dose CA (5 mg/kg), diabetic rats treated with high-dose CA (10 mg/kg). After 2 weeks of diabetic induction, CA was given orally for 2 weeks.
resultsCA significantly ameliorated histological alterations in Achilles tendons and improved locomotor behavior in the open-field test. These effects were associated with restoration of superoxide dismutase (SOD) activity and suppression of AGER expression. SCX expression, which was initially reduced in diabetic rats, was restored following CA treatment in a dose-dependent manner.
conclusionCA demonstrates a high therapeutic potential in diabetic tendinopathy by restoring antioxidant defense and modulating AGER-related signaling pathways.
Indexed as
Identifiers
42228158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.